Evidence map›Paper›PMID 41545406›Full record

ReviewNPJ Parkinson's disease2026

Unraveling the intersection of aging and Parkinson's disease: a collaborative roadmap for advancing research models.

M Y Schmidt, A M Cuervo, K L Double, D Ehninger, M S Goldberg, K Harvey, J H J Hoeijmakers, K C Luk, P G Mastroberardino, D J Moore and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

M Y SchmidtBuck Institute for Research on Aging, Novato, CA, USA.
A M CuervoInstitute for Aging Research, Albert Einstein College of Medicine, New York, NY, USA.
K L DoubleBrain and Mind Centre and School of Medical Sciences (Neuroscience), Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
D EhningerTranslational Biogerontology Lab, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
M S GoldbergDepartment of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA.
K HarveyDepartment of Pharmacology, UCL School of Pharmacy, University College London, London, UK.
J H J HoeijmakersDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
K C LukDepartment of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
P G MastroberardinoDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
D J MooreDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.
L J NiedernhoferInstitute on the Biology of Aging and Metabolism, Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
L É TrudeauDepartment of Pharmacology and Physiology, Department of Neurosciences, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
D JurkMayo Clinic, Department of Physiology and Biomedical Engineering, Robert and Arlene Kogod Center on Aging, Rochester, MN, USA.
J K Andersen *Buck Institute for Research on Aging, Novato, CA, USA. jandersen@buckinstitute.org.
I Bellantuono *School of Medicine and Population Health, Healthy Lifespan Institute, University of Sheffield, Sheffield, UK. I.bellantuono@sheffield.ac.uk.

Funding

Targeting Cellular Senescence to Extend HealthspanP01AG062413 · NIA · MAYO CLINIC ROCHESTER · 2023 to 2025
$9.1M
Michael J. Fox Foundation for Parkinson's Research MJFF-022769NIA NIH HHS P01 AG031782NIA NIH HHS P01 AG062413NIH/NIA AG062413
6 · The paper itself

Abstract

Aging is the most significant risk factor for Parkinson's disease (PD), yet its role remains underexplored. The International Network for Parkinson's Disease Modelling and Aging (PD-AGE), funded by the Michael J. Fox Foundation, was established to address these challenges. Through collaborative efforts, the PD-AGE mouse-model working group developed a roadmap to prioritize mouse models, reach consensus on experimental approaches, and standardize protocols to investigate the intersection of aging and PD.

Identifiers

PMID41545406
PMCPMC12847943

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.